2019年南非《利福平耐药结核病管理临床指南》解读及与我国《耐药结核病化学治疗指南(2019年)》对比  

Interpretation of Clinical Guidelines for the management of Rifampicin-resistant Tuberculosis in South Africa(2019)and its comparison with Guidelines for Drug-resistant Tuberculosis Chemotherapy in China(2019)

作　　者：冯莹 任斐 FENG Ying;REN Fei(Department of Drug-resistant Tuberculosis,Xi’an Chest Hospital,Shaanxi 710100,China)

机构地区：[1]西安市胸科医院耐药结核科,710100

出　　处：《中国防痨杂志》2021年第3期295-298,共4页Chinese Journal of Antituberculosis

基　　金：陕西省科技厅重点研发计划项目(2018SF-254)。

摘　　要：介绍2019年南非《利福平耐药结核病管理临床指南》的要点,包括耐药结核病治疗方案的制订、药品选择、特殊人群的治疗、密切接触者的管理等,并与我国《耐药结核病化学治疗指南(2019年)》对比,对于不同之处进行分析。To interpret the Clinical Guidelines for the management of Rifampicin-resistant Tuberculosis in South Africa(2019),including how to choose drugs,formulate treatment regimens as well as how to treat special patients,manage close contacts;and then to compare this South Africa Guidelines with the Guidelines for Drug-resistant Tuberculosis Chemotherapy in China(2019).

关 键 词：结核 抗多种药物性 方案评价 指南 对比研究 评论 

分 类 号：R52[医药卫生—内科学]